WhaleCreep

Saturn V Capital Management LP 13F holdings, Q4 2025

Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →

Saturn V Capital Management LP disclosed 20 US equity positions worth $544.9m in its Q4 2025 13F filing. The largest position was ABVX at 16.1% of the reported book, followed by AMLX and COGT. Against the Q3 2025 filing, it opened 8 new positions, added to 4 and reduced 8 among the top 20 holdings.

← Q3 2025 · Q1 2026 →

What did Saturn V Capital Management LP own in Q4 2025? Top 20 positions

#StockSectorWeightValueSharesΔ sharesvs Q3 2025
1 ABVX ABIVAX SA 16.1%$87.5m649,179 -19% reduced
2 AMLX AMYLYX PHARMACEUTICALS INC Healthcare 10.0%$54.3m4,496,487 -2% reduced
3 COGT COGENT BIOSCIENCES INC Healthcare 7.9%$43.2m1,217,064 -40% reduced
4 JAZZ JAZZ PHARMACEUTICALS PLC Healthcare 7.7%$42.2m248,070 -17% reduced
5 PCVX VAXCYTE INC Healthcare 6.8%$36.9m798,940 1% added
6 DYN DYNE THERAPEUTICS INC Healthcare 6.4%$35.0m1,788,616 -33% reduced
7 PHVS PHARVARIS N V 5.8%$31.6m1,140,033 29% added
8 CELC CELCUITY INC Healthcare 5.8%$31.6m317,095 -33% reduced
9 ALMS ALUMIS INC 5.6%$30.6m3,135,953 – new
10 IRON DISC MEDICINE INC Healthcare 4.3%$23.7m298,429 -12% reduced
11 XFOR X4 PHARMACEUTICALS INC 4.3%$23.2m5,800,530 – new
12 MNPR MONOPAR THERAPEUTICS INC 3.9%$21.3m325,701 110% added
13 IVVD INVIVYD INC Healthcare 3.5%$19.1m7,735,386 – new
14 OCUL OCULAR THERAPEUTIX INC Healthcare 3.4%$18.3m1,504,880 31% added
15 IMMX IMMIX BIOPHARMA INC 2.9%$15.7m2,999,169 – new
16 OCULIS HOLDING AG 1.9%$10.3m516,761 – new
17 IKT INHIBIKASE THERAPEUTICS INC 1.5%$7.9m3,856,799 – new
18 CNTA CENTESSA PHARMACEUTICALS PLC 1.3%$7.1m282,692 -62% reduced
19 OVID OVID THERAPEUTICS INC Healthcare 0.7%$4.1m2,500,000 – new
20 IVA INVENTIVA SA 0.2%$1.3m283,166 – new

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.